Document is current
Any future updates will be listed below
-
Authors
Vianini, Elena https://orcid.org/0009-0002-1507-1939
Pandey, Anuja https://orcid.org/0000-0002-4526-2835
Rolland, Catherine https://orcid.org/0009-0004-6962-2008
Ngubane, Nomxolisi
Mueller-Wieland, Dirk https://orcid.org/0000-0002-8807-6442
Gilbert, Jeremy https://orcid.org/0000-0001-7456-9396
Ahmad, Alhussein https://orcid.org/0000-0003-1000-8308
- License Information
-
More Information
Article History
Received: 27 January 2025
Accepted: 6 March 2025
First Online: 27 March 2025
Declarations
:
: Dr. Elena Vianini, Nomxolisi Ngubane, and Ahmad Alhussein are employed by Boehringer Ingelheim. Dr. Catherine Rolland and Dr. Anuja Pandey are employed by Evidera, a part of Thermo Fisher Scientific, which provides consulting and other research services to pharmaceutical, medical device, and related organizations. In their salaried positions, they work with a variety of companies and organizations and are precluded from receiving payment or honoraria directly from these organizations for services rendered. Evidera received funding from Boehringer Ingelheim to participate in the study and the development of this manuscript. Dr. Jeremy Gilbert declares the following conflicts of interest: Astra Zeneca, Abbott, Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Dexcom, Pfizer, HSL therapeutics, Novartis, GSK, Sanofi, Novo Nordisk. Dr. Dirk Müller-Wieland has acted as a consultant and has served on the speaker bureau for Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
